Cipla's wholly owned subsidiary -- InvaGen Pharmaceuticals Inc., USA has completed the first stage closing of Avenue Therapeutics Inc., transaction representing an acquisition of 33.3% stake in Avenue's capital stock on fully diluted basis on February 08, 2019.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
